One large debt for MannKind as firm aims to add $370m to $550m hole for Afrezza trials
This article was originally published in Scrip
Executive Summary
MannKind needs new capital for additional work and operating expenses related to its inhaled Afrezza (insulin human[rDNA origin]) using its next-generation inhaler. But the route it has chosen might not be all that smooth, some believe.